BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C (BIP48II/III)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2011 by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Sponsor:
Collaborator:
Hospital de Clinicas de Porto Alegre
Information provided by (Responsible Party):
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
ClinicalTrials.gov Identifier:
NCT01623336
First received: June 13, 2012
Last updated: June 15, 2012
Last verified: November 2011
  Purpose

The purpose of the study is to demonstrate the noninferiority of BIP48 (48 kDa peginterferon alfa-2b) compared to Pegasys ® (40 kDa peginterferon alfa-2a) associated with ribavirin, in naive patients with chronic hepatitis C.


Condition Intervention Phase
Chronic Hepatitis C
Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
Drug: Peginterferon alfa 2a 40kDA
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Efficacy of BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C: Randomized, Multicentric Study With Blinded Analysis

Resource links provided by NLM:


Further study details as provided by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz):

Primary Outcome Measures:
  • The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment. [ Time Frame: HCV PCR will be measured at 24 weeks after the end of therapy (week 48 for genotypes 2 and 3 and week 72 for genotype 1) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Frequency of adverse events [ Time Frame: Clinical exam, blood tests and immunogenicity evaluation will be done twice monthly, in the first month, and then monthly until the end of treatment( week 24 for genotypes 2 and 3 and week 48 for genotype 1). ] [ Designated as safety issue: Yes ]
    Blood tests included: ALT, AST, Creatinine and complete blood count. Anti-interferon immunoglobulin and thyroid-stimulating hormone (TSH) will be measured in the weeks 12, 24, 36, 48, 60 and 72 of the study.

  • Virologic response at the end of treatment [ Time Frame: Viral load will be measured at the end of treatment (week 24 for genotypes 2 and 3 and week 48 for genotype 1) ] [ Designated as safety issue: No ]
    Viral load will be measured by quantitative PCR at the end of treatment.


Estimated Enrollment: 740
Study Start Date: January 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pegasys ®
Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
Other Name: BIP 48 (Peginterferon alfa 2b 48kDA)
Drug: Peginterferon alfa 2a 40kDA
Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
Other Name: Pegasys ®
Experimental: BIP 48 (Peginterferon alfa 2b 48kDA)
Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
Other Name: BIP 48 (Peginterferon alfa 2b 48kDA)

Detailed Description:

The study will be an open, multicenter, randomized, controlled phase II - III trial. Patients (n = 740) will be randomized (1:1) to receive BIP48 (peginterferon alfa-2b 48kDa) or Pegasys ® (peginterferon alfa-2a 40kDa) 180 micrograms ,subcutaneously,once a week,associated with ribavirin at a dose 1000-1250 mg, orally, daily. For genotype 1 treatment time will be 48 to 72 weeks and for genotypes 2 and 3, 24 to 48 weeks. The study's population will be naive patients, of both sex, between 18 and 70 years old, with chronic hepatitis C (HCV), genotypes 1, 2 or 3, from 18 to 25 Brazilian research centers. Diagnostic criteria will be as followed: positive anti-HCV and qualitative PCR, liver biopsy showing any degree of fibrosis and at least mild inflammatory activity, performed in the last 24 months. The interruption Criteria will be: no partial virological response at 12 weeks and positive quantitative PCR at week 24.The primary outcome will be the rate of sustained virologic response and the secondary endpoints will be the quality of life during treatment, frequency of adverse events and cost-effectiveness. As a substudy, will be performed a comparative assessment in 24 patients, evaluating viral kinetics, pharmacokinetics and pharmacodynamics of repeated doses of both alfapeginterferons .

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. anti-HCV positive;
  2. viral load of HCV positive;
  3. viral genotypes 1, 2 or 3;
  4. the absence of previous treatment for chronic hepatitis C;
  5. liver biopsy performed in the last 36 months classified by Metavir score as at least A1, with any degree of fibrosis ;
  6. age from 18 to 70 years old;
  7. hemoglobin greater than 11 g / dl;
  8. platelet count higher than 75.000/mm3;
  9. neutrophils higher than 1.500/mm3;
  10. use of, at least two contraceptive methods during treatment and up to 36 weeks after the last dose of study medication (for male or female subjects in fertile age );
  11. concordance and signing of the informed consent.

Exclusion Criteria:

  1. decompensated cirrhosis (Child-Pugh score> 6);
  2. history of bleeding gastroesophageal varices;
  3. hemoglobinopathies;
  4. hepatocellular carcinoma;
  5. co-infection with HIV or HBV;
  6. other coexisting chronic liver disease, as autoimmune hepatitis, Wilson disease, hemochromatosis, chronic obstructive cholestatic disease or autoimmune disease, alcoholic liver disease;
  7. malignancies except basal cell carcinoma in situ or cervix carcinoma;
  8. systemic autoimmune diseases, except compensated autoimmune thyroid diseases ;
  9. uncontrolled seizures;
  10. primary immunodeficiencies;
  11. myelosuppression;
  12. coagulation disorders;
  13. thrombophilias;
  14. thrombopathy ;
  15. decompensated heart failure;
  16. chronic renal failure;
  17. diagnosis of other comorbidity that would compromise the subject's participation in the research study as judged by the investigator (eg, neuropsychiatric diseases, systemic infection or antibiotic use within 4 weeks, decompensated diabetes mellitus, ischemic heart disease, heart failure, respiratory or renal or uncontrolled hypertension);
  18. prior organ transplantation, except cornea;
  19. alcohol consumption exceeding 20g/day for women and 40g/dia for men during the past six months;
  20. use of illicit drugs in the previous six months;
  21. use of immunosuppressive agents during the previous six months;
  22. pregnancy or lactation;
  23. male research subjects whose sexual partner is pregnant;
  24. previous treatment with IFN or ribavirin in the last 6 months prior to inclusion;
  25. subjects with hypersensibility to IFN alpha and / or any of its components;
  26. subjects with hypersensibility to ribavirin and / or any of its ingredients;
  27. participation in another clinical study in the last 12 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01623336

Contacts
Contact: Valeria Lucia de S. Gil, ASCLIN 552138827199 valeria.lucia@bio.fiocruz.br
Contact: Maria de Lourdes de S. Maia, ASCLIN 552138829479 lourdes.maia@bio.fiocruz.br

Locations
Brazil
Ufrgs/Hcpa Recruiting
Porto Alegre, Rio Grande do Sul, Brazil
Contact: Maria de Lourdes S. Maia, ASCLIN    552138829479    mlourdes@bio.fiocruz.br   
Contact: Vivian Rotman, ASCLIN    552138829474    vivian.rotman@bio.fiocruz.br   
Principal Investigator: Paulo D. Picon, PI         
Sub-Investigator: Guilherme B. Sander, Coord         
Sub-Investigator: Luiz E. Mazzoleni, Coord         
Sponsors and Collaborators
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Hospital de Clinicas de Porto Alegre
Investigators
Principal Investigator: Paulo D. Picon, Invest Hospital de Clínicas de Porto Alegre
Study Director: Guilherme B. Sander, Coord Hospital de Clínicas de Porto Alegre
Study Director: Luiz E. Mazzoleni, Coord Hospital de Clínicas de Porto Alegre
Study Chair: André C. Wortmann, Monitor NUCLIMED
Study Chair: Karine M. Amaral, Coordenação NUCLIMED
Study Chair: Marisa B. Costa, Sub Coord NUCLIMED
Study Chair: Tobias C. Milbradt, Coord Log. NUCLIMED
Study Chair: Indara C. Saccilotto, Coordenação NUCLIMED
Study Chair: Amanda Quevedo, Sub Coord NUCLIMED
Study Chair: Daiana V. Gomes, AssitSocial NUCLIMED
  More Information

Additional Information:
No publications provided

Responsible Party: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
ClinicalTrials.gov Identifier: NCT01623336     History of Changes
Other Study ID Numbers: 11/0468
Study First Received: June 13, 2012
Last Updated: June 15, 2012
Health Authority: Brazil: The Immunobiological Technology Institute (BIO-Manguinhos)/Oswaldo Cruz Foundation

Keywords provided by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz):
HEPATITIS
HEPATITIS C
PEGINTERFERON
BIOEQUIVALENCE
TREATMENT

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Interferon-alpha
Peginterferon alfa-2b
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 22, 2014